首页> 外文期刊>Biological & pharmaceutical bulletin >Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib.
【24h】

Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib.

机译:自微乳化给药系统的配方设计,可提高塞来昔布的口服生物利用度。

获取原文
获取原文并翻译 | 示例

摘要

Celecoxib is a hydrophobic and highly permeable drug belonging to class II of biopharmaceutics classification system. Low aqueous solubility of celecoxib leads to high variability in absorption after oral administration. Cohesiveness, low bulk density and compressibility, and poor flow properties of celecoxib impart complications in it's processing into solid dosage forms. To improve the solubility and bioavailability and to get faster onset of action of celecoxib, the self-microemulsifying drug delivery system (SMEDDS) was developed. Composition of SMEDDS was optimized using simplex lattice mixture design. Dissolution efficiency, t(85%), absorbance of diluted SMEDDS formulation and solubility of celecoxib in diluted formulation were chosen as response variables. The SMEDDS formulation optimized via mixture design consisted of 49.5% PEG-8 caprylic/capric glycerides, 40.5% mixture of Tween20 and Propylene glycol monocaprylic ester (3:1) and 10% celecoxib, which showed significantly higher rate and extent of absorption than conventional capsule. The relative bioavailability of the SMEDDS formulation to the conventional capsule was 132%. The present study demonstrated the suitability of mixture design to optimize the compositions for SMEDDS. The developed SMEDDS formulations have the potential to minimize the variability in absorption and to provide rapid onset of action of celecoxib.
机译:塞来昔布是一种疏水性和高渗透性药物,属于生物药物分类系统的II类。塞来昔布的低水溶性导致口服给药后吸收变化很大。塞来昔布的内聚性,低堆积密度和可压缩性以及不良的流动性使它在加工成固体剂型时遇到了麻烦。为了提高塞来昔布的溶解度和生物利用度并使其更快起效,开发了自微乳化药物递送系统(SMEDDS)。使用单纯形晶格混合物设计优化了SMEDDS的组成。选择溶解度t(85%),稀释的SMEDDS制剂的吸光度和塞来昔布在稀释的制剂中的溶解度作为响应变量。通过混合物设计优化的SMEDDS配方由49.5%PEG-8辛酸/癸酸甘油酯,40.5%Tween20和丙二醇单辛酸酯(3:1)和10%celecoxib的混合物组成,显示出比常规药物更高的吸收速率和程度胶囊。 SMEDDS制剂相对于常规胶囊的相对生物利用度为132%。本研究表明混合物设计的适宜性,以优化SMEDDS的组成。开发的SMEDDS配方具有最大程度地减少吸收变异性和提供塞来昔布作用迅速的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号